AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
äŒæ¥ã³ãŒãABBV
äŒç€ŸåAbbVie Inc
äžå Žæ¥Jan 02, 2013
æé«çµå¶è²¬ä»»è
ãCEOãMichael (Robert A)
åŸæ¥å¡æ°55000
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jan 02
æ¬ç€Ÿæåšå°1 N Waukegan Rd
éœåžNORTH CHICAGO
蚌åžååŒæNASDAQ OMX NASDAQ Basic NYSE
åœUnited States of America
éµäŸ¿çªå·60064
é»è©±çªå·18479327900
ãŠã§ããµã€ãhttps://www.abbvie.com/
äŒæ¥ã³ãŒãABBV
äžå Žæ¥Jan 02, 2013
æé«çµå¶è²¬ä»»è
ãCEOãMichael (Robert A)